证券代码：301166 证券简称：优宁维 公告编号：2025-074 主要经营场所：上海市奉贤区八字桥路1660号2幢一层 近日，弘盛厚德已完成相关工商变更登记手续，并取得上海市市场监督管理 局下发的《登记通知书》。本次工商变更登记后，弘盛厚德的基本登记信息如下： 名称：上海弘盛厚德私募投资基金合伙企业（有限合伙） 统一社会信用代码：91310000MACBY86121 企业类型：有限合伙企业 执行事务合伙人：上海弘盛君浩股权投资基金管理有限公司 出资额：57,071万人民币 成立时间：2023年3月15日 上海优宁维生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、对外投资情况概述 上海优宁维生物科技股份有限公司（以下简称"公司"）于2025年8月18日与 上海睿昂基因科技股份有限公司（以下简称"睿昂基因"）、上海弘盛君浩股权 投资基金管理有限公司共同签署了《基金份额转让协议》，同意受让睿昂基因持 有的上海弘盛厚德私募投资基金合伙企业（有限合伙）（以下简称"弘盛厚德" 或"合伙企业"）1,500万元财产份额。本次转让完成后，公司成为弘 ...

Core Viewpoint - Shanghai Jianhui Information Technology Co., Ltd. has announced the transfer of 15 million shares of the Shanghai Hongsheng Houde Private Equity Fund to Huang Zhihong for a transfer price of RMB 0, aiming to optimize its investment structure and focus on its core business [2][3][15]. Group 1: Transaction Overview - The company participated in the establishment of the Hongsheng Houde private equity fund in 2023, with a total fund size of RMB 570.71 million and a duration of 7 years, targeting investments in the healthcare industry [3]. - The company is a general partner in the fund, with a subscribed capital of RMB 30 million, of which RMB 15 million has been paid [3]. - The transfer agreement allows the company to transfer its unpaid capital contribution of RMB 15 million to Huang Zhihong, with the transfer price set at RMB 0 [3][8]. Group 2: Fund and Transfer Details - The Hongsheng Houde fund is a limited partnership established on March 15, 2023, with a total capital of RMB 570.71 million [6]. - The fund's main activities include private equity investment, investment management, and asset management, subject to registration with the Asset Management Association of China [7]. - The transfer does not involve any debt transfer, and the ownership of the fund shares is clear, with no encumbrances or legal disputes affecting the transfer [7][9]. Group 3: Impact on the Company - The transfer of the fund shares is part of the company's strategy to streamline external investments and focus on its main business, aligning with its overall strategic planning [15]. - The transaction is not expected to have a significant impact on the company's financial status or operational activities, nor does it harm the interests of shareholders, especially minority investors [15].